Please assess the completion status of the following clinical trial:

Trial Title: Candesartan in Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years and over and to be treated with Vincristine for non-Hodgkin B lymphoma (first line treatment)~* All the patients have to be treated with the same chemotherapy protocol (CHOP with or without Rituximab) to avoid confounding factors~* Normal renal function as measured by CKD-EPI \> 30 mmol / min / 1.73 m2~* Serum potassium \< 5.5 mmol / l~* Systolic arterial pressure \> 100 mm Hg (lying and standing position)~* affiliated with a social security~* For women of childbearing age: under highly effective contraception and negative pregnancy test at inclusion. Highly effective contraception:~  * Combined hormonal contraceptive (containing estrogen and progesterone) (oral, intravaginal, or transdermal) or only progesterone (oral, injectable or implantable),~Exclusion Criteria:~* Patients with pre-existing neuropathy, Chronic ethylism, HIV infection, etc.~* Patients under guardianship or unable for another reason to give informed consent.~* Intolerance to sartans~* Intolerance to excipients : galactose , lactose.~* Patients already treated with ACE inhibitors, ARBs or/and diuretics sparing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Candesartan (Type: EXPERIMENTAL): None
- Usual care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).